Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial

Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer

“…Product efficacy and safety profiles were estimated using data obtained from published clinical trials. 1,2,11 Estimates of survival related to androgen suppression and CAB from the literature vary widely. [12][13][14] The Prostate Cancer Trialists' Collaborative Group 11 reports a meta-analysis of trials of androgen suppression versus CAB and concludes that flutamide plus an LHRH agonist confers a 2% improvement in survival over androgen suppression alone.…”

“…2 Haematuria has been reported to occur significantly more frequently for metastatic patients on bicalutamide plus an LHRH agonist compared with patients on flutamide plus an LHRH agonist (Po0.007). 1 In developing the survey, we were concerned that we were presenting very bleak prospects to men who had only recently been diagnosed with prostate cancer. To minimize the potential impact of this, we explained carefully the nature of the survey and the fact that the treatments were for a more advanced stage of the disease than they themselves had.…”

“…These hormonal therapies may be differentiated according to efficacy (time to progression and/or survival), tolerability profile, cost, convenience (once-a-day dosing versus three times per day) and/or means of administration. 1 For example, CAB with bicalutamide is associated with a reduced risk of gastrointestinal problems versus CAB with flutamide, but may have a higher risk of haematuria. 2 However, it is assumed that these side effects are likely considered by the patient to be much less important than the potential for the treatment to prolong survival.…”

Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer—a pilot study

“…In the context of combined androgen blockade (CAB) with an LHRHa, bicalutamide 50 mg od has been compared to flutamide 250 mg tds. 3 In the first report of the latter study, there was a similar incidence of flare 4 between the 2 groups.…”

Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?

“…However, in the MAB setting, diarrhoea was found to be less frequent with bicalutamide therapy than with flutamide (12 vs 26%; P < 0.001). 46 Overall, withdrawal from therapy due to adverse events occurred for 10 and 16% of patients receiving bicalutamide and flutamide, respectively. Furthermore, there were fewer withdrawals due to diarrhoea in the bicalutamide group than in flutamide-treated patients (0.5 vs 6%).…”